BR112015021525A2 - composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de tansportadores - Google Patents
composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de tansportadoresInfo
- Publication number
- BR112015021525A2 BR112015021525A2 BR112015021525A BR112015021525A BR112015021525A2 BR 112015021525 A2 BR112015021525 A2 BR 112015021525A2 BR 112015021525 A BR112015021525 A BR 112015021525A BR 112015021525 A BR112015021525 A BR 112015021525A BR 112015021525 A2 BR112015021525 A2 BR 112015021525A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- active agent
- agent nanoparticles
- transporter
- dry pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
1/1 resumo composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de transportadores são previstas aqui composições farmacêuticas secas adequadas para administração por via transmucosa, compreendendo partículas secas, tais como partículas secas por pulverização, que ncluem nanopartículas de agente farmaceuticamente ativo com um diâmetro de granulometria média antes do processamento inferior a cerca de 1µm, e em que até 10% das partículas secas por pulverização tem uma granulometria de menos de 10 µm; pelo menos 50% das partículas secas por pulverização tem uma granulometria de pelo menos cerca de 15 µm; e pelo menos 90% das partículas secas por pulverização tem uma granulometria de até cerca de 55 µm. também são previstos métodos para fazer tais composições farmacêuticas e métodos terapêuticos compreendendo administração por via transmucosa das composições, tais como intranasal ou intravaginalmente, ou por outras vias de administração.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361772095P | 2013-03-04 | 2013-03-04 | |
| US61/772,095 | 2013-03-04 | ||
| PCT/US2014/019833 WO2014137877A1 (en) | 2013-03-04 | 2014-03-03 | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015021525A2 true BR112015021525A2 (pt) | 2017-07-18 |
| BR112015021525B1 BR112015021525B1 (pt) | 2022-06-14 |
Family
ID=47901822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015021525-4A BR112015021525B1 (pt) | 2013-03-04 | 2014-03-03 | Composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de tansportadores |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10695295B2 (pt) |
| EP (1) | EP2964199B1 (pt) |
| JP (1) | JP6564708B2 (pt) |
| CN (1) | CN105307639B (pt) |
| AU (1) | AU2014226192B2 (pt) |
| BR (1) | BR112015021525B1 (pt) |
| CA (1) | CA2901015A1 (pt) |
| CY (1) | CY1124635T1 (pt) |
| DK (1) | DK2964199T3 (pt) |
| ES (1) | ES2804702T3 (pt) |
| HR (1) | HRP20201103T1 (pt) |
| HU (1) | HUE050050T2 (pt) |
| IL (1) | IL240867B (pt) |
| LT (1) | LT2964199T (pt) |
| MX (1) | MX2015011624A (pt) |
| PL (1) | PL2964199T3 (pt) |
| PT (1) | PT2964199T (pt) |
| RS (1) | RS60481B1 (pt) |
| RU (1) | RU2715714C2 (pt) |
| SI (1) | SI2964199T1 (pt) |
| WO (1) | WO2014137877A1 (pt) |
| ZA (1) | ZA201505852B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE050050T2 (hu) | 2013-03-04 | 2020-11-30 | Besins Healthcare Lu Sarl | Hordozórészecskékhez kötõdõ hatóanyag nanorészecskéket tartalmazó száraz gyógyászati kompozíciók |
| EP3493789A2 (en) | 2016-08-05 | 2019-06-12 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical powder compositions |
| US20200179277A1 (en) * | 2017-05-19 | 2020-06-11 | Milton S. Jackson | Appetite suppressant |
| JP7453770B2 (ja) | 2019-10-25 | 2024-03-21 | 松本油脂製薬株式会社 | 複合粒子及びその製造方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59163313A (ja) | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| FR2575678B1 (fr) | 1985-01-04 | 1988-06-03 | Saint Gobain Vitrage | Ejecteur pneumatique de poudre |
| DK546289D0 (da) * | 1989-11-02 | 1989-11-02 | Danochemo As | Carotenoidpulvere |
| IE67345B1 (en) * | 1991-03-12 | 1996-03-20 | Akzo Nv | Low dose dry pharmaceutical preparations |
| GB9211268D0 (en) * | 1992-05-28 | 1992-07-15 | Ici Plc | Salts of basic peptides with carboxyterminated polyesters |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5958458A (en) | 1994-06-15 | 1999-09-28 | Dumex-Alpharma A/S | Pharmaceutical multiple unit particulate formulation in the form of coated cores |
| KR100568436B1 (ko) * | 1996-02-27 | 2007-04-25 | 데이진 가부시키가이샤 | 분말상경비투여조성물 |
| CA2341732C (en) | 1998-08-26 | 2008-08-19 | Teijin Limited | Powder composition for nasal administration |
| US6117446A (en) * | 1999-01-26 | 2000-09-12 | Place; Virgil A. | Drug dosage unit for buccal administration of steroidal active agents |
| ES2236007T3 (es) | 1999-12-08 | 2005-07-16 | Pharmacia Corporation | Composiciones de inhibidor de ciclooxigenasa-2 ue tiene un efecto terapeutico rapido. |
| US6906027B2 (en) | 2001-07-05 | 2005-06-14 | Translational Research Ltd. | Composition for nasal administration of insulin |
| CN1176649C (zh) | 2002-10-16 | 2004-11-24 | 上海医药工业研究院 | 舒马普坦干粉吸入剂及其制备方法 |
| PL211224B1 (pl) | 2003-01-31 | 2012-04-30 | Orexo Ab | Kompozycja farmaceutyczna do leczenia ostrych zaburzeń przez podjęzykowe lub donosowe podawanie oraz jej zastosowanie |
| US7638138B2 (en) | 2003-02-21 | 2009-12-29 | Translational Research, Ltd. | Compositions for nasal administration of pharmaceuticals |
| EP1785145A4 (en) | 2004-08-10 | 2008-08-13 | Translational Res Ltd | TRANSNASAL COMPOSITION WITH IMMEDIATE EFFECT AND HIGH RESORBIBILITY |
| US7947308B2 (en) | 2005-07-20 | 2011-05-24 | Raimar Loebenberg | Effervescent powders for inhalation |
| EP1973523A2 (en) | 2005-12-15 | 2008-10-01 | Acusphere, Inc. | Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration |
| WO2007117661A2 (en) | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries Ltd, | Drug microparticles |
| GB0625322D0 (en) * | 2006-12-19 | 2007-01-24 | Pharmakodex Ltd | Pharmaceutical compositions |
| EP2116264B1 (en) | 2006-12-26 | 2017-09-27 | Shin Nippon Biomedical Laboratories, Ltd. | Preparation for transnasal application |
| GB0716907D0 (en) | 2007-08-31 | 2007-10-10 | Archimedes Dev Ltd | Pharmaceutical powder compositions |
| US20110250274A1 (en) * | 2008-09-19 | 2011-10-13 | Shaked Ze Ev | Estriol formulations |
| WO2010131486A1 (en) | 2009-05-15 | 2010-11-18 | Shin Nippon Biomedical Laboratories, Ltd. | Intranasal pharmaceutical compositions with improved pharmacokinetics |
| AU2010253776B2 (en) * | 2009-05-29 | 2015-01-22 | Pearl Therapeutics, Inc. | Compositions for pulmonary delivery of long-acting muscarinic antagonists and long-acting B2 adrenergic receptor agonists and associated methods and systems |
| US20110262502A1 (en) | 2010-02-08 | 2011-10-27 | Prairie Pharmaceuticals LLC | Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc) |
| WO2011133956A1 (en) * | 2010-04-22 | 2011-10-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| JP2014504260A (ja) * | 2010-10-15 | 2014-02-20 | グラクソ グループ リミテッド | 集合ナノ粒子状薬物製剤、その製造及び使用 |
| EP2540281A1 (en) * | 2011-06-30 | 2013-01-02 | LEK Pharmaceuticals d.d. | Solid self-microemulsifying systems |
| HUE050050T2 (hu) | 2013-03-04 | 2020-11-30 | Besins Healthcare Lu Sarl | Hordozórészecskékhez kötõdõ hatóanyag nanorészecskéket tartalmazó száraz gyógyászati kompozíciók |
-
2014
- 2014-03-03 HU HUE14710757A patent/HUE050050T2/hu unknown
- 2014-03-03 WO PCT/US2014/019833 patent/WO2014137877A1/en active Application Filing
- 2014-03-03 ES ES14710757T patent/ES2804702T3/es active Active
- 2014-03-03 US US14/195,023 patent/US10695295B2/en active Active
- 2014-03-03 LT LTEP14710757.7T patent/LT2964199T/lt unknown
- 2014-03-03 CA CA2901015A patent/CA2901015A1/en not_active Abandoned
- 2014-03-03 PL PL14710757T patent/PL2964199T3/pl unknown
- 2014-03-03 EP EP14710757.7A patent/EP2964199B1/en active Active
- 2014-03-03 CN CN201480011817.7A patent/CN105307639B/zh active Active
- 2014-03-03 SI SI201431571T patent/SI2964199T1/sl unknown
- 2014-03-03 RU RU2015141792A patent/RU2715714C2/ru active
- 2014-03-03 BR BR112015021525-4A patent/BR112015021525B1/pt active IP Right Grant
- 2014-03-03 AU AU2014226192A patent/AU2014226192B2/en active Active
- 2014-03-03 MX MX2015011624A patent/MX2015011624A/es active IP Right Grant
- 2014-03-03 PT PT147107577T patent/PT2964199T/pt unknown
- 2014-03-03 RS RS20200797A patent/RS60481B1/sr unknown
- 2014-03-03 JP JP2015561494A patent/JP6564708B2/ja active Active
- 2014-03-03 DK DK14710757.7T patent/DK2964199T3/da active
-
2015
- 2015-08-14 ZA ZA2015/05852A patent/ZA201505852B/en unknown
- 2015-08-26 IL IL240867A patent/IL240867B/en active IP Right Grant
-
2020
- 2020-06-25 US US16/911,598 patent/US10918601B2/en active Active
- 2020-06-25 CY CY20201100589T patent/CY1124635T1/el unknown
- 2020-07-14 HR HRP20201103TT patent/HRP20201103T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL240867A0 (en) | 2015-10-29 |
| JP2016510742A (ja) | 2016-04-11 |
| SI2964199T1 (sl) | 2020-10-30 |
| IL240867B (en) | 2020-11-30 |
| RU2015141792A3 (pt) | 2018-03-01 |
| LT2964199T (lt) | 2020-08-10 |
| WO2014137877A1 (en) | 2014-09-12 |
| HUE050050T2 (hu) | 2020-11-30 |
| US10918601B2 (en) | 2021-02-16 |
| DK2964199T3 (da) | 2020-06-15 |
| BR112015021525B1 (pt) | 2022-06-14 |
| US10695295B2 (en) | 2020-06-30 |
| CN105307639A (zh) | 2016-02-03 |
| JP6564708B2 (ja) | 2019-08-21 |
| PL2964199T3 (pl) | 2021-01-25 |
| MX2015011624A (es) | 2015-12-17 |
| ES2804702T3 (es) | 2021-02-09 |
| RU2015141792A (ru) | 2017-04-07 |
| CA2901015A1 (en) | 2014-09-12 |
| AU2014226192A1 (en) | 2015-09-03 |
| CY1124635T1 (el) | 2022-03-24 |
| EP2964199A1 (en) | 2016-01-13 |
| HRP20201103T1 (hr) | 2021-02-05 |
| ZA201505852B (en) | 2017-07-26 |
| US20140248367A1 (en) | 2014-09-04 |
| EP2964199B1 (en) | 2020-04-22 |
| US20200390706A1 (en) | 2020-12-17 |
| PT2964199T (pt) | 2020-05-12 |
| RU2715714C2 (ru) | 2020-03-03 |
| CN105307639B (zh) | 2020-06-30 |
| AU2014226192A8 (en) | 2016-04-21 |
| AU2014226192B2 (en) | 2018-07-26 |
| RS60481B1 (sr) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015501882A1 (en) | Respirable agglomerates of porous carrier particles and micronized drug | |
| ES2721898T3 (es) | Formulaciones estables para liofilizar partículas terapéuticas | |
| MX354828B (es) | Polvos secos de cationes metálicos monovalentes para inhalación. | |
| NI201600093A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
| DOP2019000250A (es) | Composicion farmaceutica que comprende selexipag | |
| AR093181A1 (es) | Formulacion con contenido de enzimas digestivas bajo estable | |
| BR112015021525A2 (pt) | composições farmacêuticas secas compreendendo nanopartículas de agente ativo ligadas a partículas de tansportadores | |
| CO2017012670A2 (es) | Unidad de dosificación orodispersable que contiene un componente estetrol | |
| BR112013019540A2 (pt) | formulações de pó seco de partículas que contêm dois ou mais ingredientes ativos para o tratamento de doenças obstrutivas ou inflamatórias das vias aéreas | |
| CL2018003178A1 (es) | Composición farmacéutica | |
| MX357601B (es) | Nanoparticula polimerica de finasterida, composicion acuosa que contiene la misma, composicion para el tratamiento de alopecia, metodo para preparar la composicion y su uso. | |
| IN2013MU03583A (pt) | ||
| HN2011000864A (es) | Particulas inhalables que comprenden tiotropio | |
| BR112015020443A2 (pt) | desamorfização de formulações secadas por atomização via mistura por atomização | |
| AR093012A1 (es) | Composiciones farmaceuticas en polvo, activas, con enmascaramiento del sabor y procesos para su fabricacion | |
| CO2019003876A2 (es) | Formulación farmacéutica parenteral que contiene ácido carglúmico | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| PE20142444A1 (es) | Nueva composicion de alfentanilo para el tratamiento del dolor agudo | |
| MY191712A (en) | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation | |
| PH12015502717A1 (en) | Anti-fibrogenic compounds, methods and uses thereof | |
| PE20070529A1 (es) | Composicion farmaceutica que contiene azodicarbonamida micronizada y su preparacion | |
| CO6420321A2 (es) | Un derivado de cianopirimidina novedoso | |
| BR112015010651A2 (pt) | composição antiparasitária de amplo espectro de nitazoxanida, probióticos e prebióticos | |
| AR070974A1 (es) | Formulacion en suspension para adsorbentes de carbono | |
| CL2007001713A1 (es) | Composicion farmaceutica oral en forma de suspension acuosa que comprende particulas del antihelmintico carbamato de bencimidazol con un 90% de tamano promedio menor que 450 nm y un surfactante polisorbato; metodo para su preparcion; metodo para preparar un medicamento; y uso para controlar infecciones parasitarias en animales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/03/2014, OBSERVADAS AS CONDICOES LEGAIS |